Penumbra Reports Positive Data for Pulmonary Embolism Treatment

Dow Jones

Nov 04, 2025

By Katherine Hamilton

Penumbra reported positive data for a trial of its treatment for pulmonary embolism.

The use of computer-assisted vacuum thrombectomy resulted in improvements in thrombus burden reduction, heart rate, oxygen requirement and functional outcomes in patients with the blood-clot disorder, Penumbra said.

A significantly higher share of patients treated with CAVT returned to normalization within 48 hours compared to those who weren't treated with it, the Alameda, Calif., company said Monday. They had lower heart rates and were able to walk longer distances following treatment.

The results show CAVT can rapidly and safely improve patient outcomes, Chief Medical Officer James Benenati said. He said the treatment should be considered as a therapeutic option for patients with acute intermediate to high risk pulmonary embolism.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

November 03, 2025 15:26 ET (20:26 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2580247694"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2580247694\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2580247694?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 04:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580247694","market":"nz","top_or_hot":-1,"title":"Penumbra Reports Positive Data for Pulmonary Embolism Treatment","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Penumbra reported positive data for a trial of its treatment for pulmonary embolism. \n</p>\n<p>\n  The use of computer-assisted vacuum thrombectomy resulted in improvements in thrombus burden reduction, heart rate, oxygen requirement and functional outcomes in patients with the blood-clot disorder, Penumbra said. \n</p>\n<p>\n  A significantly higher share of patients treated with CAVT returned to normalization within 48 hours compared to those who weren't treated with it, the Alameda, Calif., company said Monday. They had lower heart rates and were able to walk longer distances following treatment. \n</p>\n<p>\n  The results show CAVT can rapidly and safely improve patient outcomes, Chief Medical Officer James Benenati said. He said the treatment should be considered as a therapeutic option for patients with acute intermediate to high risk pulmonary embolism. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 03, 2025 15:26 ET (20:26 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Penumbra Reports Positive Data for Pulmonary Embolism Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPenumbra Reports Positive Data for Pulmonary Embolism Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-11-04 04:26</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Penumbra reported positive data for a trial of its treatment for pulmonary embolism. \n</p>\n<p>\n  The use of computer-assisted vacuum thrombectomy resulted in improvements in thrombus burden reduction, heart rate, oxygen requirement and functional outcomes in patients with the blood-clot disorder, Penumbra said. \n</p>\n<p>\n  A significantly higher share of patients treated with CAVT returned to normalization within 48 hours compared to those who weren't treated with it, the Alameda, Calif., company said Monday. They had lower heart rates and were able to walk longer distances following treatment. \n</p>\n<p>\n  The results show CAVT can rapidly and safely improve patient outcomes, Chief Medical Officer James Benenati said. He said the treatment should be considered as a therapeutic option for patients with acute intermediate to high risk pulmonary embolism. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 03, 2025 15:26 ET (20:26 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4548","symbol_name":"巴美列捷福持仓","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2580247694","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580247694","pubTimestamp":1762201560,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Penumbra reported positive data for a trial of its treatment for pulmonary embolism.The use of computer-assisted vacuum thrombectomy resulted in improvements in thrombus burden reduction, heart rate, oxygen requirement and functional outcomes in patients with the blood-clot disorder, Penumbra said.A significantly higher share of patients treated with CAVT returned to normalization within 48 hours compared to those who weren't treated with it, the Alameda, Calif., company said Monday. They had lower heart rates and were able to walk longer distances following treatment.The results show CAVT can rapidly and safely improve patient outcomes, Chief Medical Officer James Benenati said. He said the treatment should be considered as a therapeutic option for patients with acute intermediate to high risk pulmonary embolism.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4548":"巴美列捷福持仓","BK4082":"医疗保健设备","PEN":"Penumbra Inc"},"translate_title":"Penumbra报告肺栓塞治疗的积极数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PEN":1.5},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  Penumbra reported positive data for a trial of its treatment for pulmonary embolism. \n\n\n  The use of computer-assisted vacuum thrombectomy resulted in improvements in thrombus burden reduction, heart rate, oxygen requirement and functional outcomes in patients with the blood-clot disorder, Penumbra said. \n\n\n  A significantly higher share of patients treated with CAVT returned to normalization within 48 hours compared to those who weren't treated with it, the Alameda, Calif., company said Monday. They had lower heart rates and were able to walk longer distances following treatment. \n\n\n  The results show CAVT can rapidly and safely improve patient outcomes, Chief Medical Officer James Benenati said. He said the treatment should be considered as a therapeutic option for patients with acute intermediate to high risk pulmonary embolism. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 03, 2025 15:26 ET (20:26 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}